-transparent.png){kind=logo}
Sixteen patients with prostatic carcinoma were treated with 200 mg of Cyproterone acetate daily. No other kind of hormonal treatment was administered. Increasing skeletal metastases were observed in 6 patients, whereas significant reduction of metastases took place in 2 patients. Objective relief of stranguria was observed only in 3 patients. The amount of residual urine increased in 3 patients and was reduced in 5. In about one third of the patients, the prostate gland became smaller and softer. The acidic phosphatases decreased from pathological to normal values in 7 patients. There were no observed hepatic, renal or haemotological side-effects. However, serious cardio-vascular complications occurred in 6 patients, while arterial hypertension developed in 4. It is suggested that Cyproterone acetate cannot be recommended as the only kind of hormonal treatment of prostatic cancer.
K J Tveter, and
B Otnes, and
R Hannestad
January 1996,
Khirurgiia,
K J Tveter, and
B Otnes, and
R Hannestad
January 1973,
The Journal of urology,
K J Tveter, and
B Otnes, and
R Hannestad
August 1985,
Lancet (London, England),
K J Tveter, and
B Otnes, and
R Hannestad
November 1980,
The Journal of clinical endocrinology and metabolism,
K J Tveter, and
B Otnes, and
R Hannestad
January 1997,
International urology and nephrology,
K J Tveter, and
B Otnes, and
R Hannestad
January 1990,
European urology,
K J Tveter, and
B Otnes, and
R Hannestad
June 1989,
BMJ (Clinical research ed.),
K J Tveter, and
B Otnes, and
R Hannestad
January 1987,
Progress in clinical and biological research,
K J Tveter, and
B Otnes, and
R Hannestad
September 1993,
Annals of oncology : official journal of the European Society for Medical Oncology,
K J Tveter, and
B Otnes, and
R Hannestad
August 1976,
British journal of urology,
